AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
His early efforts were focused on monocyclic beta-lactam antibiotics, exemplified by the monobactam aztreonam, and culminated in the identification of a pre-clinical drug candidate, U-78608, a potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results